Photys Therapeutics has debuted with a $75 million Series A funding round. The startup focuses on phosphorylation-inducing chimeric small molecules (PHICS) — a new class of bifunctional medicines that can direct and repair protein phosphorylation.
Photys Therapeutics has debuted with a $75 million Series A funding round. The startup focuses on phosphorylation-inducing chimeric small molecules (PHICS) — a new class of bifunctional medicines that can direct and repair protein phosphorylation.
Copyright © 2024 | WordPress Theme by MH Themes